Metabolic Syndrome and Asthma

Recent Pat Endocr Metab Immune Drug Discov. 2014 Jan;8(1):60-6. doi: 10.2174/1872214807666140107151023.

Abstract

Metabolic syndrome (MetS) is a syndrome that involves at least three disorders dyslipidemia, insulin resistance, obesity and/or hypertension. MetS has been associated with several chronic diseases in the adulthood; however, in the recent years, the syndrome was redefined in children. Girls with early menarche and asthma, and children with MetS and asthma that reach adulthood appear to have higher risk to develop severe or difficult to control asthma and a higher probability to suffer cardiovascular diseases. It has been proposed that patients with MetS and endocrinological disorders should be considered a different entity in which pharmacologic treatment should be adjusted according to the individual. Recent patents on the field have addressed new issues on how endocrine control should be managed along with asthma therapeutics. In the near future, new approaches should decrease the high morbidity and mortality associated to these types of patients.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aging / physiology
  • Asthma / drug therapy*
  • Asthma / epidemiology
  • Asthma / therapy*
  • Comorbidity
  • Humans
  • Immunotherapy
  • Metabolic Syndrome / drug therapy*
  • Metabolic Syndrome / epidemiology
  • Metabolic Syndrome / therapy*
  • Patents as Topic*